Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

With Two Deals In Place, Amerigen Looks To Leverage China For Branded Generics

This article was originally published in PharmAsia News

Executive Summary

U.S. startup looks to tap into China’s generic market – both in China and back home in the states.

You may also be interested in...



Pfizer Looks To Ramp Up Branded Generics Via MOU With China's Hisun

Pfizer Inc. and Shanghai-based Zhejiang Hisun Pharmaceuticals announced June 2 a memorandum of understanding to potentially establish a joint venture to develop, manufacture and sell branded generics in China and other markets

Shanghai Fosun Omni Pharma Execs On China Following A Different Pharma Model Than India: An Interview With PharmAsia News (Part 1 of 2)

Shanghai Fosun Omni Pharmaceutical was founded in 2006 as a JV between two former principal R&D leaders from Ivax/Tevaand Shanghai Fosun Pharmaceutical, a leading pharmaceutical enterprise in China. Shanghai-based Omni's CEO Kai Zhang and COO Shaochuan Zeng, the two former leaders from Ivax/Teva, spoke with PharmAsia News about their operation and Chinese pharmas going international.

Key Role For China As Sanofi’s Emerging Markets Business Grows

Continuing with a double-digit growth rate, China remained a leading driver for Sanofi’s global business in the fourth quarter. Going digital and building local partnerships emerged as key themes for Sanofi China to explore more opportunities, although it may face testing problems for its vaccine business in the country.

Topics

Related Companies

UsernamePublicRestriction

Register

SC080467

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel